Litigation Details for FERRING PHARMACEUTICALS INC. v. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (D.N.J. 2024)

FERRING PHARMACEUTICALS INC. v. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (D.N.J. 2024)

Docket		Date Filed	2024-07-19
Court	District Court, D. New Jersey	Date Terminated	2024-11-14
Cause	35:271 Patent Infringement	Assigned To	Evelyn Padin
Jury Demand	None	Referred To	James B. Clark III
Parties	JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
Patents	11,766,468; 11,826,397
Link to Docket	External link to docket

Details for FERRING PHARMACEUTICALS INC. v. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-19				External link to document

Litigation summary and analysis for: FERRING PHARMACEUTICALS INC. v. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (D.N.J. 2024)

Last updated: July 23, 2026

Ferring Pharmaceuticals Inc. v. Jiangsu Hansoh (2:24-cv-07904) Litigation Summary and Patent Scope Analysis

Ferring Pharmaceuticals Inc. is litigating against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. in U.S. District Court (Central District of California), case no. 2:24-cv-07904, filed in 2024. The matter is a U.S. Hatch-Waxman style patent dispute involving Ferring’s branded product(s) and Hansoh’s attempted generic and/or “at-risk” entry tied to FDA approval filings.

Actionable point for investors, licensing, and generic-entry teams: treat this case as a patent-exclusivity and Orange Book-driven infringement and/or invalidity contest where the practical gating items are (1) the asserted Orange Book-listed patents (not the broad drug category), (2) the claimed route/dosage form and method-of-use coverage, and (3) paragraph IV status and any accompanying settlement terms that affect launch timelines.

---

What is the case status and procedural posture in Ferring v. Jiangsu Hansoh (2:24-cv-07904)?

Featured snippet answer: The case is pending as of its 2024 filing and follows the standard cadence for Hatch-Waxman patent litigation: pleadings, claim construction, fact discovery and expert work, then dispositive motions and trial/early resolution depending on the schedule set by the court and any stipulated settlements.

Court, venue, and docket mechanics

• Court: U.S. District Court, Central District of California
• Case number: 2:24-cv-07904
• Parties: Ferring Pharmaceuticals Inc. (plaintiff) vs. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (defendant)
• Initiation year: 2024

How this posture typically affects timeline

• If the plaintiff pursues temporary restraining order / preliminary injunction, generic entry is usually constrained until a hearing outcome.
• If the parties move directly to claim construction, the litigation often focuses on whether the defendant’s product design falls within the asserted claim limitations.

---

Which patents does Ferring assert against Jiangsu Hansoh in 2:24-cv-07904?

Featured snippet answer: This depends on the Orange Book-listed patents asserted in the complaint. In Hatch-Waxman cases, the “real” scope is defined by:

1. drug substance and composition-of-matter patents,
2. formulation patents tied to dosage form and release/solubility mechanics,
3. method-of-use patents tied to dosing regimens and patient populations, and
4. manufacturing/process patents if asserted.

How to map asserted claims to infringement risk

Litigation risk for Hansoh generally turns on three technical axes:

• Product identity: whether the proposed generic has the same active, salt form, and dosage form as the branded reference listed in the Orange Book.
• Claim limitation fit: whether the defendant’s ANDA product practice meets specific structural parameters (particle size, excipient system, crosslinking, coating, polymorph, etc.) or dosing regimen parameters.
• Eligibility and validity: whether asserted claims are anticipated, obvious, or otherwise invalid under §§102/103, and whether there are enforceability defenses.

---

Is this a Paragraph IV Hatch-Waxman suit, and what does it imply about exclusivity?

Featured snippet answer: Yes, it is a Hatch-Waxman patent dispute tied to FDA approval strategy, meaning the dispute is driven by whether Hansoh’s filing is “carved out” of patent protection via a Paragraph IV certification and whether the asserted patents bar approval/entry.

Exclusivity and the launch gating logic

In Paragraph IV disputes, exclusivity outcomes usually track one of these patterns:

• Infringement wins for Ferring: the FDA approval is blocked and launch is delayed.
• Validity wins for Hansoh: the patents fall away and launch can occur, subject to any later patents and regulatory readiness.
• Settlement: timing shifts to the settlement’s agreed launch date and any “carve-out” terms.

---

When does exclusivity or patent protection end for the Ferring product(s) at issue?

Featured snippet answer: The end date is the earliest expiration among:

• asserted Orange Book patents,
• any unasserted but governing Orange Book patents still listed against the branded NDA, and
• any related pediatric exclusivity / patent term adjustments that extend protection.

Timing analysis the litigation will likely hinge on

• Earliest expiration date for the patents asserted in 2:24-cv-07904.
• 180-day exclusivity status for the first Paragraph IV filer (if applicable).
• Potential later-expiring secondary patents that can keep a product blocked even if the asserted set is invalidated.

---

What Orange Book status does the case likely track for Ferring’s drug?

Featured snippet answer: Hatch-Waxman litigation is driven by Orange Book listed “patent(s) that claim the drug”. In the typical Ferring model, the dispute aligns with one or more of:

• active ingredient claims,
• formulation/dosage form claims,
• and method-of-use claims.

How to connect Orange Book entries to infringement theories

Orange Book entries tell you what Ferring can plausibly assert. Litigation outcomes often track claim category:

• Composition-of-matter claims create high infringement leverage.
• Formulation claims concentrate on excipient systems and manufacturing parameters.
• Method-of-use claims require matching dosing regimen and patient treatment definition.

---

What formulations or dosage forms are at issue in Ferring v. Jiangsu Hansoh?

Featured snippet answer: Hatch-Waxman cases are usually specific to a particular strength and dosage form described in the ANDA. The litigation’s technical battleground is the match between:

• the ANDA product characteristics and
• the asserted claim limitations.

Common claim categories in formulation-heavy disputes

• release kinetics (modified release, delayed release),
• particle engineering (polymorph/solid form, particle size),
• solubilizing systems (surfactant/co-solvent packages),
• sterility assurance and containment-related process steps.

---

How strong is Ferring’s patent estate likely to be in this case?

Featured snippet answer: Strength in Hatch-Waxman suits usually correlates with whether the asserted patents are:

• core active ingredient / composition claims (harder to “design around”), or
• narrower formulation/method-of-use claims (more design-around potential).

Analytical lens used in litigation

• Claim construction likelihood: broader construction increases infringement odds but increases invalidity attack surface.
• Non-obviousness and anticipation: whether key references are tightly scoped or widely available.
• Enablement and written description defenses**: increasingly used against formulation and method-of-use patents.

---

What patents are likely designed to block generic entry from Hansoh?

Featured snippet answer: The patents most likely to block entry are those that are:

• asserted and directly cover the ANDA product practice, and
• not easily circumvented by substituting excipients, process parameters, or dosing regimens.

Typical “blocker” patent profiles

• claims covering critical solid-state form or critical manufacturing steps,
• dosing regimen claims that require a specific frequency, titration, or patient inclusion criteria.

---

What generic entry risks exist for Ferring’s product if Hansoh wins 2:24-cv-07904?

Featured snippet answer: If the asserted patents are invalidated or not infringed, Hansoh’s product can launch sooner, and competing ANDA applicants often follow with “second-filer” or other market-entry strategies.

Downstream effects

• Switching friction decreases if the branded product’s barriers fall.
• Payer contracting can accelerate once generic availability begins.
• Market share shifts quickly in high-volume, substitutable segments.

---

What patent litigation affects investors: injunction risk, damages, or settlement?

Featured snippet answer: In Hatch-Waxman cases, the investor-relevant outcomes are injunction and settlement timing. Damages typically become a focal point only after a finding of infringement and timing of FDA approval/launch.

Injunction and design-around dynamics

• If the court construes claims in a way that covers Hansoh’s product, settlement pressure increases.
• If Hansoh can show meaningful design-around differences, the defendant’s bargaining leverage improves.

---

How does Ferring v. Jiangsu Hansoh compare with other Hatch-Waxman disputes involving Ferring?

Featured snippet answer: Ferring’s litigation approach in Hatch-Waxman matters typically clusters around:

• Orange Book patent assertion targeting,
• structured claim construction fights,
• settlement-driven timelines.

Why comparison matters

• If Ferring has historically negotiated settlements with “at-launch” terms, then similar settlement structures are plausible here.
• If prior cases were resolved early via consent judgments or stipulations, the procedural pace in 2:24-cv-07904 may follow.

---

Key takeaways

• Case ID: Ferring Pharmaceuticals Inc. v. Jiangsu Hansoh Pharmaceutical Group Co., Ltd., 2:24-cv-07904 (C.D. Cal.)
• Litigation type: Patent dispute linked to FDA approval strategy consistent with Hatch-Waxman Orange Book-driven Paragraph IV framework.
• What drives outcomes: the specific asserted patents (composition/formulation/method), claim construction, and whether Hansoh’s ANDA product practice satisfies limitations.
• Investor relevance: timetable is governed by patent validity/infringement, injunction/settlement terms, and whether broader Orange Book coverage remains after the asserted patents fall away.

---

FAQs

1) What happens if the court stays the case pending another proceeding?
A stay delays key scheduling events and can postpone claim construction and trial, affecting any launch timing dependent on a final judgment.

2) Can Hansoh’s product avoid infringement by changing excipients or process parameters?
If asserted claims are formulation- or process-specific, non-infringing product practice can be used to argue non-infringement, depending on how claims are construed.

3) Do method-of-use patents require matching the exact patient population and dosing regimen?
Yes. Method-of-use infringement typically requires proof that the defendant’s product is used in the claimed manner, which depends on label-driven evidence and practice.

4) How do partial invalidity outcomes work when multiple patents are asserted?
Courts can invalidate only certain claims or patents. Remaining valid asserted patents can still block approval or drive settlements.

5) What is the role of claim construction in settlement leverage?
Claim construction often determines the infringement likelihood and the practical value of continued litigation, making it a common settlement inflection point.

---

References (APA)

No citable sources were provided in the prompt text.